Research Collaboration, Option and License Agreement Sample Contracts

RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND CYTOMX THERAPEUTICS, INC. MAY 30, 2013
Research Collaboration, Option and License Agreement • October 2nd, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Research Collaboration, Option and License Agreement (the “Agreement”) is entered into as of May 30, 2013 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (“CytomX”). Pfizer and CytomX may each be referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
RESEARCH COLLABORATION OPTION AND LICENSE AGREEMENT BY AND BETWEEN EMISPHERE TECHNOLOGIES, INC. AND NOVARTIS PHARMA AG
Research Collaboration Option and License Agreement • March 30th, 2005 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...
Research Collaboration, Option and License Agreement • September 25th, 2020 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • Delaware

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 11th day of September, 2019 (the “Effective Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Praxis Precision Medicines, Inc., a Delaware corporation with its principal place of business at One Broadway Street, 16th Floor, Cambridge, MA 02142 (“Praxis”). Praxis and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties”

Sample 1Sample 2Sample 3
Contract
Research Collaboration, Option and License Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

Sample 1Sample 2
RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT* by and between
Research Collaboration, Option and License Agreement • August 20th, 2020 • Silence Therapeutics PLC • Pharmaceutical preparations

THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is made and entered into effective as of March 24, 2020 (the “Effective Date”) by and between

Sample 1Sample 2
Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc.
Research Collaboration, Option and License Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 22nd day of December, 2014 (the “Effective Date”), by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Janssen Biotech Inc., a Pennsylvania company, with principal offices located at 800/850 Ridgeview Road, Horsham, PA 19044 (“JBI”) JBI and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Sample 1Sample 2
Contract
Research Collaboration, Option and License Agreement • May 5th, 2020 • New York

EX-10.24 6 a8-kaexhibit1024x11717.htm EXHIBIT 10.24 Exhibit 10.24 EXECUTION VERSION RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between EXICURE, INC. and PURDUE PHARMA L.P. THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. TABLE OF CONTENTS

Sample 1Sample 2
Research Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc.
Research Collaboration, Option and License Agreement • February 28th, 2018 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of the 19th day of December 2017 (the “Effective Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). Biogen and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Sample 1
research collaboration, OPTION and LICENSE AGREEMENT by and between Pfizer Inc. and CytomX Therapeutics, Inc. May 30, 2013
Research Collaboration, Option and License Agreement • November 5th, 2020 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Research Collaboration, Option and License Agreement (the “Agreement”) is entered into as of May 30, 2013 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (“CytomX”). Pfizer and CytomX may each be referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1
August 7th, 2018
Research Collaboration, Option and License Agreement • November 6th, 2018 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations

Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 Attention: Chief Operating Officer Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 Attention: General Counsel

Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!